Stock Financial Ratios

WVE / WAVE Life Sciences Ltd. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,014.58
Enterprise Value ($M)298.52
Book Value ($M)134.86
Book Value / Share5.91
Price / Book6.12
NCAV ($M)152.66
NCAV / Share6.70
Price / NCAV7.08
Income Statement (mra) ($M)
Net Income-55.40
Balance Sheet (mrq) ($M)
Cash & Equivalents168.46
Cash / Share7.39
Quick Ratio12.50
Current Ratio12.50
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.41
Return on Assets (ROA)-0.34
Return on Equity (ROE)-0.41
Identifiers and Descriptors
Central Index Key (CIK)1631574
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Share Statistics
Common Shares Outstanding (M)27.79
Scoring Models
Piotroski F Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Equity Per Share7.27
Accounts Payable Per Share0.00
Inventory Per Share0.00
Cash Per Share7.39
Assets Current Per Share7.62
Liabilities And Stock Equity Per Share8.86
Liabilities Other Non Current Per Share0.04
Assets Other Non Current Per Share0.00
Intangibles Per Share0.00
Inventory Work In Progress Per Share0.00
Goodwill Per Share0.00
Property Plant And Equipment Net Per Share1.08
Retained Earnings Per Share-7.12
Debt Per Share0.00
Assets Per Share8.86
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Liabilities Current Per Share0.66
Liabilities Per Share1.24
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Cash And Equivalents Per Share7.39
Accumulated Depreciation And Depletion Per Share0.00
Additional Paid In Capital Per Share0.83
Minority Interest Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share1.08

Related News Stories

Dicerna Pharmaceuticals: Buy The Dip

2017-12-19 seekingalpha
Shares rose by as much as 225% in the past six months before the recent pullback. (19-1)

Your Daily Pharma Scoop: A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tumbles

2017-11-16 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (381-9)

Wave Life Sciences: DMD Program Set To Create Value In 2018

2017-11-07 seekingalpha
It is thought that significantly improved exon 51 skipping efficiency and dystrophin protein restoration observed in preclinical studies could translate into an improved second-generation treatment. (32-1)

Hold On To Alnylam Pharmaceuticals In 2017

2017-11-01 seekingalpha
Striding incessantly towards the target of having three commercialized products in its portfolio by end of year 2020, Alnylam Pharmaceuticals (NASDAQ:ALNY) is definitely a very interesting investment opportunity in 2017. The year 2017 has proved to be pivotal for the company, with lead investigational RNAi drug, Patisiran, demonstrating high level of efficacy as well as strong safety profile in polyneuropathy related to hereditary ATTR or hATTR amyloidosis indication, in the phase 3, APOLLO trial. (81-0)

CUSIP: Y95308105